Clinical-grade, at-home testing for HPV, STIs, vaginal health, and hormones. Trusted by healthcare providers nationwide.
99.2% valid result rate
Comparable diagnostic accuracy to clinician-collected sampling, with significantly higher conclusive result rates in clinical trials.
Why providers choose Daye
Clinical-Grade Accuracy
FDA 510(k) cleared menstrual tampon and validated in peer-reviewed studies. Our at-home collection methods match or exceed traditional clinic-based testing performance.
Seamless Integration
Patients test at home, and results return to your dashboard in 3-5 days—with clinical recommendations included.
Improved Patient Access
Remove barriers to screening. Our at-home solutions increase testing uptake by 40-60%, particularly among underserved or underscreened populations.
“We’ve found that patients are far more comfortable using a tampon-based collection method compared to swabs. This has improved adherence and reduced the number of insufficient samples, which ultimately speeds up treatment timelines.”
1
2
3
4
HPV diagnostic accuracy
In a head-to-head comparison, the Diagnostic Tampon showed 82.9% sensitivity, 91.6% specificity, and a 99.2% conclusive result rate, performing comparably to clinician-collected samples and outperforming vaginal self-swabs.
STI detection
Across comparative studies, the tampon showed high concordance with clinician-collected samples for Chlamydia trachomatis, Neisseria gonorrhoeae, and Bacterial Vaginosis.
Microbiome Profiling
Tampon-based sampling generated more abundant microbial DNA—significantly increasing total bacterial mass and key taxa such as Lactobacillus and Ureaplasma.
Patient Acceptability
Across multiple cohorts, the majority of participants were willing to provide tampon samples, with a strong preference over both speculum exams and vaginal swabs, including among first-time screeners and those with GSM-related discomfort.
One tampon, multiple panels
The higher analyte yield from tampon sampling enables HPV, STI, and microbiome analysis from a single specimen, reducing patient burden and improving workflow efficiency.
99.2%
Conclusive HPV result rate in the STAMP accuracy study
100%
Willingness to provide a tampon sample across multiple cohorts
0%
Positive agreement for Gonorrhoea & BV in paired comparisons
